Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093863 | 0.97 | HRH3 (0.51) | HRH3KCNH2MAPTKMT2ANPSR1 | |
| SCHEMBL1096047 | 0.97 | HRH3 (0.51) | HRH3KCNH2MAPTKMT2ANPSR1 | |
| SCHEMBL1093918 | 0.86 | HRH3 (0.65) | HRH3KCNH2 | |
| SCHEMBL1095586 | 0.86 | HRH3 (0.65) | HRH3KCNH2 | |
| SCHEMBL1096156 | 0.85 | HRH3 (0.67) | HRH3KCNH2 | |
| SCHEMBL1094350 | 0.85 | HRH3 (0.67) | HRH3KCNH2 | |
| SCHEMBL1094352 | 0.85 | HRH3 (0.67) | HRH3KCNH2 | |
| SCHEMBL1095208 | 0.85 | HRH3 (0.67) | HRH3KCNH2 | |
| SCHEMBL1096154 | 0.85 | HRH3 (0.67) | HRH3KCNH2 | |
| SCHEMBL1095939 | 0.84 | HRH3 (0.49) | HRH3KCNH2MAPTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153813-B2 | Benzothiazole and benzooxazole derivatives and methods of use | ABBOTT LABORATORIES (US) | 2012-04-10 | — | — | US | claimed |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | claimed |
| US-8580968-B2 | Benzothiazole and benzooxazole derivatives and methods of use | ABBVIE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120164070-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153813-B2 | Benzothiazole and benzooxazole derivatives and methods of use | ABBOTT LABORATORIES (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164070-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | HRH2, HRH1, HRH4 | HRH3 4/4885KCNH2 2847/4885MAPT 2328/4885 |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | HRH2, HRH1, HRH4 | HRH3 4/4885KCNH2 2847/4885MAPT 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.